We did not back doubling of Covishield dosing gap – Indian scientists


The Indian government doubled the gap between the two doses of the Covishield vaccine without the agreement of the scientific group that it said recommended the increase, three members of the advisory body informed.

The ministry of health announced the decision to change the gap from 6-8 weeks to 12-16 weeks on May 13, at a time when supplies of the shot were falling short of demand and infections were surging across the country.

It said the extended gap was recommended by the National Technical Advisory Group on Immunisation (NTAGI), based on real-life evidence mainly from Britain. Yet, the NTAGI scientists, classified by the government as three of the 14 core members, said the body did not have enough data to make such a recommendation.

M.D. Gupte, a former director of the state-run National Institute of Epidemiology, said the NTAGI had backed increasing the dosing interval to 8-12 weeks – the gap advised by the World Health Organization. But he added that the group had no data concerning the effects of a gap beyond 12 weeks.

“Eight to 12 weeks is something we all accepted, but 12 to 16 weeks is something the government has come out with. This may be alright, may not be. We have no information on that,” he added.

This was echoed by his NTAGI colleague Mathew Varghese, who said the group’s recommendation was only for 8-12 weeks.

The health ministry, citing the head of NTAGI’s working group on COVID-19, said that the dosing decision was based on scientific evidence. “There were no dissenting voices among the NTAGI members,” the ministry said on Twitter.

The ministry’s statement on May 13 said that it had accepted the 12-16 weeks recommendation from NTAGI’s COVID working group, as had a group of mainly government officials tasked with vaccine administration, known as NEGVAC.

Government health officials told a news conference on May 15 the gap was not increased to address a vaccine shortage but was a scientific decision.

J.P. Muliyil, a member of the seven-strong COVID working group, said there had been discussions within the NTAGI on increasing the vaccine dosage interval but that the body had not recommended 12-16 weeks.

“That specific number was not quoted,” he said, without elaborating.

N.K. Arora, the COVID working group head, declined to comment on its recommendations but said all its decisions were taken collectively by the NTAGI at large.

A NEGVAC representative said it respects the decisions of the NTAGI and uses them for our work, declining to elaborate.


Please enter your comment!
Please enter your name here